Amneal Pharmaceuticals has patented a method for treating Parkinson’s disease using controlled release levodopa compositions. Patients switch from immediate release tablets to controlled release forms, resulting in decreased “Off” time. The multiparticulate dosage form includes a core coated with muco-adhesive and enteric coating polymers, along with an immediate release component. GlobalData’s report on Amneal Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Amneal Pharmaceuticals, was a key innovation area identified from patents. Amneal Pharmaceuticals's grant share as of May 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
Controlled release levodopa compositions for treating parkinson's disease
A recently granted patent (Publication Number: US11986449B2) discloses a method for treating patients diagnosed with Parkinson's disease. The method involves discontinuing the administration of oral immediate release levodopa tablets and instead administering multiparticulate controlled release levodopa dosage forms. These dosage forms are designed to provide a more sustained release of levodopa, resulting in a decrease of at least 10% in the patient's total post-dose "Off" time compared to the immediate release tablets. The multiparticulate controlled release dosage form includes a combination of controlled release components and an immediate release component, with specific dosages and formulations outlined in the claims.
Furthermore, the patent details the specific characteristics of the multiparticulate controlled release dosage form, including the composition of controlled release components, the formulation as beads, and the release profile of levodopa over time. The method also specifies the plasma levels of levodopa post-administration, the levodopa fluctuation index, and the recommended dosing regimen for optimal therapeutic effects. By providing a detailed protocol for transitioning patients from immediate release tablets to controlled release dosage forms, this method aims to improve the management of Parkinson's disease symptoms and enhance patient outcomes.
To know more about GlobalData’s detailed insights on Amneal Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
